<Page>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): OCTOBER 25, 2001
ISIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
000-19125 33-0336973
(Commission File No.) (IRS Employer Identification No.)
2292 FARADAY AVENUE
CARLSBAD, CA 92008
(Address of Principal Executive Offices and Zip Code)
Registrant's telephone number, including area code: (760) 931-9200
------------------------------
<Page>
ITEM 5. OTHER EVENTS.
On October 25, 2001, Isis Pharmaceuticals, Inc. announced that its
Ibis Therapeutics(TM) division had received an additional two-year contract
with the Defense Advanced Research Projects Agency (DARPA) to develop a
sensor to detect infectious agents used in biological warfare attacks. This
two-year contract is currently valued at up to an additional $7.1 million for
the research program Triangulation Identification Genetic Evaluation of
biological Risks (TIGER). Earlier in the month, Isis announced the receipt of
a $1.8 million award for the TIGER program, bringing the total of the TIGER
contract to up to $8.9 million. Over the past year, San Diego-based Science
Applications International Corporation (SAIC) and Ibis Therapeutics have
worked together to receive the TIGER program award. The SAIC and Ibis
Therapeutics partnership will combine Ibis' expertise in microbial genome
sequence analysis and advanced mass spectrometry technology with SAIC's
advanced signal processing capabilities.
The TIGER contract builds on the biological warfare countermeasure
research Ibis Therapeutics has conducted in two previous DARPA programs. The
preceding studies, initiated in 1997 and 1999, focused on creating a strategy to
identify common binding sites, or structured regions within RNA, to a wide range
of infectious agents in order to develop small molecules to combat infectious
pathogens. Ibis' work for DARPA has yielded a number of proprietary targets and
significant advances in RNA-targeted drug design.
ITEM 7. EXHIBITS.
10.1 Subcontract Agreement, dated October 25, 2001,
between Isis Pharmaceuticals, Inc. and Science
Applications International Corporation.
99.1 Press Release dated October 25, 2001.
1.
<Page>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
ISIS PHARMACEUTICALS, INC.
Dated: October 29, 2001 By: /s/ B. Lynne Parshall
--------------------------------------
B. LYNNE PARSHALL
Executive Vice President,
Chief Financial Officer and Director
2.
<Page>
INDEX TO EXHIBITS
10.1 Subcontract Agreement, dated October 25, 2001,
between Isis Pharmaceuticals, Inc. and Science
Applications International Corporation.
99.1 Press Release dated October 25, 2001.
3.